Home
report store
immune thrombocytopenic purpura epidemiology forecast

Immune Thrombocytopenic Purpura Epidemiology Forecast - 2036

Published Date : 2026

Pages : 60

Region : United States, Japan, EU4 & UK

Summary
TOC Table of Content
LOT
- Sample Request

Immune Thrombocytopenic Purpura Epidemiology

According to DelveInsight’s analysis, total ITP prevalent cases were around 224,600 in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.

ITP incident cases are expected to rise from 35,717 cases in 2025 to 39,438 cases by 2036. This growing prevalence reflects the disease's chronic, relapsing nature, rising incidence of secondary ITP in an aging population, and improved diagnosis through greater physician awareness and platelet-count screening. Factors that, alongside cumulative side effects of long-term corticosteroid and second-line therapies, are also driving increasing patient burden.
The United States has the largest share of prevalent cases at 36.6%, yet the EU4 and UK together account for 50.6% and Japan for 12.7%, so the patient pool is spread across many countries and does not depend on the US alone.
In the 7MM, primary ITP represented ~80% of the ITP population in 2025, while secondary ITP accounted for ~20%, reflecting the predominance of isolated autoimmune disease.
Treatment uptake among newly diagnosed ITP patients is high, with ~80–90% receiving treatment. Of these, approximately 70% of adults and 20% of children progress to chronic ITP, primarily due to inadequate response or failure of first-line treatment.

Immune Thrombocytopenic Purpura (ITP) Epidemiology Forecast in the 7MM

2025 Immune Thrombocytopenic Purpura (ITP) Total Prevalent Cases: ~ 224,600 cases
2036 Projected Immune Thrombocytopenic Purpura (ITP) Total Prevalent Cases: ~ 265,000 cases
Immune Thrombocytopenic Purpura (ITP) Growth Rate (2026–2036): 2.7% CAGR

DelveInsight's ‘Immune Thrombocytopenic Purpura (ITP) –Epidemiology Forecast – 2036’ report delivers an in-depth understanding of ITP, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Study Period	2022–2036
Historical Year	2022–2025
Forecast Period	2026–2036
Base Year	2026
Geographies Covered	North America: The US Europe: Germany, France, Italy, Spain and the UK Asia-Pacific: Japan
Immune Thrombocytopenic Purpura (ITP) Epidemiology CAGR (Forecast period)	1.5% (2026–2036)
Immune Thrombocytopenic Purpura (ITP) Epidemiology Segmentation Analysis	Patient Burden Assessment ITP Incident Cases ITP Prevalent Cases ITP Progression from Acute to Chronic ITP Prevalent Cases (included progressed cases from acute) ITP Prevalent Cases by Gender ITP Prevalent Cases by Type (Primary and Secondary) Treated Cases of Acute ITP Line-wise Treated Cases of Chronic ITP

Immune Thrombocytopenic Purpura (ITP) Understanding and Diagnosis

Immune Thrombocytopenic Purpura (ITP) Overview

Immune thrombocytopenia (ITP) is an acquired autoimmune hematologic disorder characterized by isolated thrombocytopenia (<100 × 10⁹/L) caused by immune-mediated platelet destruction and impaired platelet production. ITP may be primary or secondary to conditions such as autoimmune diseases, infections, malignancies, or drugs. Based on duration, it is classified as newly diagnosed (<3 months), persistent (3–12 months), or chronic (>12 months), with adults more likely to develop chronic disease. Pathophysiology involves autoreactive B- and T-cell activation, antiplatelet autoantibodies, impaired megakaryopoiesis, and inadequate thrombopoietin response. Patients commonly experience petechiae, purpura, mucosal bleeding, epistaxis, and heavy menstrual bleeding, while severe bleeding such as intracranial hemorrhage is rare. Fatigue and psychological burden can further impair quality of life.

Diagnosis

ITP is primarily a diagnosis of exclusion, based on isolated thrombocytopenia after ruling out other causes of low platelet counts. Diagnosis typically includes patient and family history, physical examination, Complete Blood Count (CBC) with reticulocytes, peripheral blood smear, coagulation tests, liver function tests, folate and vitamin B12 levels, immunoglobulin levels, and HIV/HBV/HCV serology. Additional evaluation may include antiphospholipid and antithyroid antibodies, thyroid function, antinuclear antibodies, and serum proteinogram. Selected patients may undergo testing for anti-glycoprotein antibodies, immature platelet fraction, H. pylori, viral infections, bone marrow examination, blood group/Rh, direct antiglobulin test, or pregnancy, based on clinical presentation. Tests such as thrombopoietin levels, bleeding time, and serum complement are generally not routinely recommended due to limited diagnostic utility.

Note: Further details are provided in the report.

Explore more insights in the report @ Immune Thrombocytopenic Purpura Treatment Market Size

Immune Thrombocytopenic Purpura (ITP) Epidemiology

Key Findings from Immune Thrombocytopenic Purpura (ITP) Epidemiological Analysis and Forecast

According to DelveInsight’s estimates, approximately 224,600 prevalent ITP cases (including cases progressed from the acute phase) were reported across the 7MM in 2025.
The UK has the highest adult ITP prevalence among the 7MM at ~0.05%. Although the underlying UK data are dated, no newer UK-specific estimates have been published, and recent sources continue to cite the same ~0.05% prevalence rate. Spain and Italy also report relatively high prevalence, but at ~0.028% and ~0.027%, respectively, approximately half the UK level.
Adults make up 90% of prevalent cases and about 80% of incident cases. The prevalent pool is overwhelmingly adult because about 70% of adults progress to persistent or chronic ITP, against about 20% of children, whose disease mostly resolves within months.
Women account for about ~60% of US prevalent ITP cases, consistent with the female skew of autoimmune disease, where immune regulation and estrogen effects may raise susceptibility.

Scope of the Report

The report covers a segment of key events, an executive summary, a descriptive overview of ITP, explaining its causes, signs and symptoms, and pathogenesis.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

ITP Patient Population Forecast

Report Key Strengths

Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
11-year forecast
Patient Burden Trends (by geography)

For more insights into the report @ Immune Thrombocytopenic Purpura Treatment Drugs

FAQs

What are the disease risks, burdens, and unmet needs of ITP? What will be the growth opportunities across the 7MM concerning the patient population with ITP?
What is the historical and forecasted ITP patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges

Stay updated with us for Recent Articles @ New DelveInsight Blogs

1: Key Insights

2: Report Introduction

3: Executive Summary of ITP

4: Epidemiology Forecast Methodology

5: Disease Background and Overview of ITP

5.1: Introduction

5.2: Classification of ITP

5.2.1: On the Basis of Etiology

5.2.1.1: Primary ITP

5.2.1.2: Secondary ITP

5.2.2: On the Basis of Duration

5.2.2.1: Newly Diagnosed (Acute) ITP

5.2.2.2: Persistent ITP

5.2.2.3: Chronic ITP

5.3: Pathophysiology of ITP

5.3.1: Autoantibodies

5.3.2: T Lymphocytes

5.3.3: Thrombopoietin

5.3.4: Impaired Megakaryopoiesis and Platelet Production

5.4: Symptoms

5.5: Diagnosis

5.5.1: Diagnosis Algorithm

5.5.2: Diagnostic Criteria

5.5.3: Differential Diagnosis

5.6: Treatment

5.7: Treatment Guidelines

5.7.1: American Society of Hematology (ASH) (2026)

5.7.2: European Expert Consensus

5.7.3: Japan Guidelines

6: Epidemiology and Patient Population of 7MM

6.1: Key Findings

6.2: Assumptions and Rationale

6.3: ITP Incident Cases in the 7MM

6.4: ITP Prevalent Cases in the 7MM

6.5: ITP Prevalent Cases (Including Progressed Cases from Acute) in the 7MM

6.6: The United States

6.6.1: ITP Incident Cases in the United States

6.6.2: ITP Prevalent Cases in the United States

6.6.3: ITP Progression from Acute to Chronic in the United States

6.6.4: ITP Prevalent Cases (Including Progressed Cases from Acute) in the United States

6.6.5: ITP Prevalent Cases by Gender in the United States

6.6.6: ITP Prevalent Cases by Type (Primary and Secondary) in the United States

6.6.7: Treated Cases of Acute ITP in the United States

6.6.8: Line-Wise Treated Cases of Chronic ITP in the United States

6.7: EU4 and the UK

6.7.1: ITP Incident Cases in EU4 and the UK

6.7.2: ITP Prevalent Cases in EU4 and the UK

6.7.3: ITP Progression from Acute to Chronic in EU4 and the UK

6.7.4: ITP Prevalent Cases (Including Progressed Cases from Acute) in EU4 and the UK

6.7.5: ITP Prevalent Cases by Gender in EU4 and the UK

6.7.6: ITP Prevalent Cases by Type (Primary and Secondary) in EU4 and the UK

6.7.7: Treated Cases of Acute ITP in EU4 and the UK

6.7.8: Line-Wise Treated Cases of Chronic ITP in EU4 and the UK

6.8: Japan

6.8.1: ITP Incident Cases in Japan

6.8.2: ITP Prevalent Cases in Japan

6.8.3: ITP Progression from Acute to Chronic in Japan

6.8.4: ITP Prevalent Cases (Including Progressed Cases from Acute) in Japan

6.8.5: ITP Prevalent Cases by Gender in Japan

6.8.6: ITP Prevalent Cases by Type (Primary and Secondary) in Japan

6.8.7: Treated Cases of Acute ITP in Japan

6.8.8: Line-Wise Treated Cases of Chronic ITP in Japan

7: Patient Journey

8: KOL Views of ITP

8.1: Expert/KOL Interview Highlights

9: Appendix

9.1: Bibliography

10: DelveInsight Capabilities

11: Disclaimer

12: About DelveInsight

List of Tables:

List of Tables

Table 1: Summary of ITP Epidemiology (2025–2036)

Table 2: Recommendations for the Study of Patients with Suspected ITP

Table 3: American Society of Hematology (ASH) Guidelines

Table 4: American Society of Hematology (2026)

Table 5: European Expert Consensus

Table 6: Japan Guidelines (2019)

Table 7: Total Incident Cases of ITP in the 7MM (2022–2036)

Table 8: Total Prevalent Cases of ITP in the 7MM (2022–2036)

Table 9: ITP Prevalent Cases (Including Progressed Cases from Acute) in the 7MM (2022–2036)

Table 10: ITP Incident Cases in the United States (2022–2036)

Table 11: ITP Prevalent Cases in the United States (2022–2036)

Table 12: ITP Progression from Acute to Chronic in the United States (2022–2036)

Table 13: ITP Prevalent Cases (Including Progressed Cases from Acute) in the United States (2022–2036)

Table 14: ITP Prevalent Cases by Gender in the United States (2022–2036)

Table 15: ITP Prevalent Cases by Type (Primary and Secondary) in the United States (2022–2036)

Table 16: Treated Cases of Acute ITP in the United States (2022–2036)

Table 17: Line-Wise Treated Cases of Chronic ITP in the United States (2022–2036)

Table 18: ITP Incident Cases in Germany (2022–2036)

Table 19: ITP Prevalent Cases in France (2022–2036)

Table 20: ITP Prevalent Cases in Italy (2022–2036)

Table 21: ITP Prevalent Cases in Spain (2022–2036)

Table 22: ITP Prevalent Cases in the UK (2022–2036)

Table 23: ITP Prevalent Cases in EU4 and the UK (2022–2036)

Table 24: ITP Prevalent Cases in Germany (2022–2036)

Table 25: ITP Prevalent Cases in France (2022–2036)

Table 26: ITP Prevalent Cases in Italy (2022–2036)

Table 27: ITP Prevalent Cases in Spain (2022–2036)

Table 28: ITP Prevalent Cases in the UK (2022–2036)

Table 29: ITP Prevalent Cases in EU4 and the UK (2022–2036)

Table 30: ITP Progression from Acute to Chronic in Germany (2022–2036)

Table 31: ITP Progression from Acute to Chronic in France (2022–2036)

Table 32: ITP Progression from Acute to Chronic in Italy (2022–2036)

Table 33: ITP Progression from Acute to Chronic in Spain (2022–2036)

Table 34: ITP Progression from Acute to Chronic in the UK (2022–2036)

Table 35: ITP Progression from Acute to Chronic in EU4 and the UK (2022–2036)

Table 36: ITP Prevalent Cases (Including Progressed Cases from Acute) in EU4 and the UK (2022–2036)

Table 37: ITP Prevalent Cases by Gender in Germany (2022–2036)

Table 38: ITP Prevalent Cases by Gender in France (2022–2036)

Table 39: ITP Prevalent Cases by Gender in Italy (2022–2036)

Table 40: ITP Prevalent Cases by Gender in Spain (2022–2036)

Table 41: ITP Prevalent Cases by Gender in the UK (2022–2036)

Table 42: ITP Prevalent Cases by Gender in EU4 and the UK (2022–2036)

Table 43: ITP Prevalent Cases by Type (Primary and Secondary) in Germany (2022–2036)

Table 44: ITP Prevalent Cases by Type (Primary and Secondary) in France (2022–2036)

Table 45: ITP Prevalent Cases by Type (Primary and Secondary) in Italy (2022–2036)

Table 46: ITP Prevalent Cases by Type (Primary and Secondary) in Spain (2022–2036)

Table 47: ITP Prevalent Cases by Type (Primary and Secondary) in the UK (2022–2036)

Table 48: ITP Prevalent Cases by Type (Primary and Secondary) in EU4 and the UK (2022–2036)

Table 49: Treated Cases of Acute ITP in EU4 and the UK (2022–2036)

Table 50: Line-Wise Treated Cases of Chronic ITP in Germany (2022–2036)

Table 51: Line-Wise Treated Cases of Chronic ITP in France (2022–2036)

Table 52: Line-Wise Treated Cases of Chronic ITP in Italy (2022–2036)

Table 53: Line-Wise Treated Cases of Chronic ITP in Spain (2022–2036)

Table 54: Line-Wise Treated Cases of Chronic ITP in the UK (2022–2036)

Table 55: Line-Wise Treated Cases of Chronic ITP in EU4 and the UK (2022–2036)

Table 56: ITP Incident Cases in Japan (2022–2036)

Table 57: ITP Prevalent Cases in Japan (2022–2036)

Table 58: ITP Progression from Acute to Chronic in Japan (2022–2036)

Table 59: ITP Prevalent Cases (Including Progressed Cases from Acute) in Japan (2022–2036)

Table 60: ITP Prevalent Cases by Gender in Japan (2022–2036)

Table 61: ITP Prevalent Cases by Type (Primary and Secondary) in Japan (2022–2036)

Table 62: Treated Cases of Acute ITP in Japan (2022–2036)

Table 63: Line-Wise Treated Cases of Chronic ITP in Japan (2022–2036)

List of Figures:

List of Figures

Figure 1: Diagnosis of Adult Primary Immune Thrombocytopenia

Figure 2: Total Incidence Cases of ITP in the 7MM (2022–2036)

Figure 3: Total Prevalent Cases of ITP in the 7MM (2022–2036)

Figure 4: ITP Prevalent Cases (Including Progressed Cases from Acute) in the 7MM (2022–2036)

Figure 5: ITP Incident Cases in the United States (2022–2036)

Figure 6: ITP Prevalent Cases in the United States (2022–2036)

Figure 7: ITP Progression from Acute to Chronic in the United States (2022–2036)

Figure 8: ITP Prevalent Cases (Including Progressed Cases from Acute) in the United States (2022–2036)

Figure 9: ITP Prevalent Cases by Gender in the United States (2022–2036)

Figure 10: ITP Prevalent Cases by Type (Primary and Secondary) in the United States (2022–2036)

Figure 11: Treated Cases of Acute ITP in the United States (2022–2036)

Figure 12: Line-Wise Treated Cases of Chronic ITP in the United States (2022–2036)

Figure 13: ITP Incident Cases in EU4 and the UK (2022–2036)

Figure 14: ITP Prevalent Cases in EU4 and the UK (2022–2036)

Figure 15: ITP Progression from Acute to Chronic in EU4 and the UK (2022–2036)

Figure 16: ITP Prevalent Cases (Including Progressed Cases from Acute) in EU4 and the UK (2022–2036)

Figure 17: ITP Prevalent Cases by Gender in EU4 and the UK (2022–2036)

Figure 18: ITP Prevalent Cases by Type (Primary and Secondary) in EU4 and the UK (2022–2036)

Figure 19: Treated Cases of Acute ITP in EU4 and the UK (2022–2036)

Figure 20: Line-Wise Treated Cases of Chronic ITP in EU4 and the UK (2022–2036)

Figure 21: ITP Incident Cases in Japan (2022–2036)

Figure 22: ITP Prevalent Cases in Japan (2022–2036)

Figure 23: ITP Progression from Acute to Chronic in Japan (2022–2036)

Figure 24: ITP Prevalent Cases (Including Progressed Cases from Acute) in Japan (2022–2036)

Figure 25: ITP Prevalent Cases by Gender in Japan (2022–2036)

Figure 26: ITP Prevalent Cases by Type (Primary and Secondary) in Japan (2022–2036)

Figure 27: Treated Cases of Acute ITP in Japan (2022–2036)

Figure 28: Line-Wise Treated Cases of Chronic ITP in Japan (2022–2036)

*The table of contents is not exhaustive; will be provided in the final report

Related Reports

Immune Thrombocytopenic Purpura Pipeline Insight, 2026

"Immune Thrombocytopenic Purpura Pipeline Insights, 2026" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across..

Immune Thrombocytopenic Purpura Market Insights, Epidemiology, and Market Forecast – 2036

DelveInsight’s Immune Thrombocytopenic Purpura Market Insights, Epidemiology and Market Forecast - 2036 report provides the detailed overview of the disease and in depth understanding of historical

License Type

Offer